Shao Ying, Lu Bingjian
Department of Surgical Pathology, Women's Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang Province, China.
Cancer Metastasis Rev. 2022 Mar;41(1):173-191. doi: 10.1007/s10555-021-10000-8. Epub 2021 Oct 18.
Unexpected resistance to anti-angiogenic treatment prompted the investigation of non-angiogenic tumor processes. Vessel co-option (VC) and vasculogenic mimicry (VM) are recognized as primary non-angiogenic mechanisms. In VC, cancer cells utilize pre-existing blood vessels for support, whereas in VM, cancer cells channel and provide blood flow to rapidly growing tumors. Both processes have been implicated in the development of tumor and resistance to anti-angiogenic drugs in many tumor types. The morphology, but rare molecular alterations have been investigated in VC and VM. There is a pressing need to better understand the underlying cellular and molecular mechanisms. Here, we review the emerging circular RNA (circRNA)-mediated regulation of non-angiogenic processes, VC and VM.
抗血管生成治疗出现的意外耐药性促使人们对非血管生成性肿瘤过程展开研究。血管共选择（VC）和血管生成拟态（VM）被认为是主要的非血管生成机制。在VC中，癌细胞利用预先存在的血管来获取支持，而在VM中，癌细胞引导并为快速生长的肿瘤提供血流。这两个过程在许多肿瘤类型的肿瘤发展和对抗血管生成药物的耐药性中都发挥了作用。在VC和VM中，人们已经对其形态进行了研究，但对分子改变的研究却很少。迫切需要更好地了解其潜在的细胞和分子机制。在此，我们综述了新兴的环状RNA（circRNA）介导的对非血管生成过程、VC和VM的调控。
